These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30959531)

  • 1. Effects of Insulin Therapy and Oral Hypoglycemic Agents on Glycemic Control for Type 2 Diabetes Mellitus Patients in China-A Case Control Study.
    Zuo P; Shi J; Yan J; Yang L; Liu C; Yuan L; Lou Q
    Exp Clin Endocrinol Diabetes; 2021 May; 129(5):374-378. PubMed ID: 30959531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intriguing effects of time to glycemic goal in newly diagnosed type 2 diabetes after short-term intensive insulin therapy.
    Cheng L; Xu M; Lin X; Tang J; Qi Y; Wan Y; Pan X; Chen X; Ren M; Yan L
    Endocr J; 2016 Aug; 63(8):739-46. PubMed ID: 27334121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia.
    Sendekie AK; Teshale AB; Tefera YG
    PLoS One; 2022; 17(5):e0268639. PubMed ID: 35617250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
    Lee SW; Lee S; Kim SH; Kim TH; Kang BS; Yoo SH; Lee MK; Koh WJ; Kang WS; Kim HJ
    Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.
    Lundershausen R; Müller S; Hashim M; Kienhöfer J; Kipper S; Wilke T
    Exp Clin Endocrinol Diabetes; 2020 Mar; 128(3):170-181. PubMed ID: 30157532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients.
    Chon S; Oh S; Kim SW; Kim JW; Kim YS; Woo JT
    Korean J Intern Med; 2010 Sep; 25(3):273-81. PubMed ID: 20830224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of early intensive therapy on islet beta cell function and long-term glycemia control in newly diagnosed type 2 diabetic patients with different fasting plasma glucose levels.].
    Li YB; Zeng LY; Shi LX; Zhu DL; Zhou ZG; Yan L; Tian HM; Luo ZJ; Yang LY; Liu J; Weng JP
    Zhonghua Nei Ke Za Zhi; 2010 Jan; 49(1):9-13. PubMed ID: 20356473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
    Ke W; Liu L; Liu J; Chen A; Deng W; Zhang P; Cao X; Liao Z; Xiao H; Liu J; Li Y
    J Diabetes Res; 2016; 2016():6839735. PubMed ID: 26640805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced.
    Yamamoto Y; Takahara M; Yasuda T; Katakami N; Matsuoka TA; Kaneto H; Shimomura I
    Endocr J; 2014; 61(9):911-9. PubMed ID: 25048394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
    Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
    Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
    Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes.
    Ryan EA; Imes S; Wallace C
    Diabetes Care; 2004 May; 27(5):1028-32. PubMed ID: 15111515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.